Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): Pooled analysis of two randomised trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study.

Abstract

4003 Background: Two randomized trials (GERCOR/GISCAD: gemcitabine [GEM] plus oxaliplatin versus Gem; German multicenter trial: Gem plus cisplatin versus Gem) indicated superior efficacy in terms of response rate and progression-free survival (PFS) for combined therapy. While a trend for prolonged overall survival (OS) was reported in these underpowered… (More)

Topics

Cite this paper

@article{Louvet2006IncreasedSU, title={Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): Pooled analysis of two randomised trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study.}, author={Christophe Louvet and Alexandra J C Hincke and Roberto Labianca and Volker Heinemann}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2006}, volume={24 18_suppl}, pages={4003} }